Patents by Inventor Simon Bubnic

Simon Bubnic has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11821004
    Abstract: Mesenchymal stem cells which express TNF-? receptor Type I in an amount of at least 13 pg/106 cells. Such mesenchymal stem cells inhibit the proliferation of lymphocytes and may be employed, in particular, in the treatment of graft-versus-host disease.
    Type: Grant
    Filed: November 2, 2020
    Date of Patent: November 21, 2023
    Assignee: MESOBLAST INTERNATIONAL SÁRL
    Inventors: Alla Danilkovitch, Diane Carter, Alicia Mildred Tyrell, Simon Bubnic, Michelle Marcelino, Rodney Monroy
  • Publication number: 20210171913
    Abstract: Mesenchymal stem cells which express TNF-? receptor Type I in an amount of at least 13 pg/106 cells. Such mesenchymal stem cells inhibit the proliferation of lymphocytes and may be employed, in particular, in the treatment of graft-versus-host disease.
    Type: Application
    Filed: November 2, 2020
    Publication date: June 10, 2021
    Applicant: Mesoblast International Sárl
    Inventors: Alla DANILKOVITCH, Diane CARTER, Alicia Mildred TYRELL, Simon BUBNIC, Michelle MARCELINO, Rodney MONROY
  • Publication number: 20180087032
    Abstract: Mesenchymal stem cells which express TNF-? receptor Type I in an amount of at least 13 pg/106 cells. Such mesenchymal stem cells inhibit the proliferation of lymphocytes and may be employed, in particular, in the treatment of graft-versus-host disease.
    Type: Application
    Filed: September 1, 2017
    Publication date: March 29, 2018
    Applicant: Mesoblast International Sárl
    Inventors: Alla DANILKOVITCH, Diane Carter, Alicia Tyrell, Simon Bubnic, Michelle Marcelino, Rodney Monroy
  • Publication number: 20150004693
    Abstract: Mesenchymal stem cells which express TNF-? receptor Type I in an amount of at least 13 pg/106 cells. Such mesenchymal stem cells inhibit the proliferation of lymphocytes and may be employed, in particular, in the treatment of graft-versus-host disease.
    Type: Application
    Filed: September 12, 2014
    Publication date: January 1, 2015
    Inventors: Alla Danilkovitch, Diane Carter, Alicia Tyrell, Simon Bubnic, Michelle Marcelino, Rodney Monroy
  • Publication number: 20140248244
    Abstract: Mesenchymal stem cells which express TNF-? receptor Type I in an amount of at least 13 pg/106 cells. Such mesenchymal stem cells inhibit the proliferation of lymphocytes and may be employed, in particular, in the treatment of graft-versus-host disease.
    Type: Application
    Filed: March 28, 2014
    Publication date: September 4, 2014
    Inventors: Alla Danilkovitch, Diane Carter, Alicia Tyrell, Simon Bubnic, Michelle Marcelino, Rodney Monroy
  • Publication number: 20130259841
    Abstract: Mesenchymal stem cells which express TNF-? receptor Type I in an amount of at least 13 pg/106 cells. Such mesenchymal stem cells inhibit the proliferation of lymphocytes and may be employed, in particular, in the treatment of graft-versus-host disease.
    Type: Application
    Filed: May 31, 2013
    Publication date: October 3, 2013
    Inventors: Alla Danilkovitch, Diane Carter, Alicia Tyrell, Simon Bubnic, Michelle Marcelino, Rodney Monroy
  • Patent number: 8486695
    Abstract: Mesenchymal stem cells which express TNF-? receptor Type I in an amount of at least 13 pg/106 cells. Such mesenchymal stem cells inhibit the proliferation of lymphocytes and may be employed, in particular, in the treatment of graft-versus-host disease.
    Type: Grant
    Filed: February 22, 2012
    Date of Patent: July 16, 2013
    Assignee: Osiris Therapeutics, Inc.
    Inventors: Alla Danilkovitch, Diane Carter, Alicia Tyrell, Simon Bubnic, Michelle Marcelino, Rodney Monroy
  • Publication number: 20120214178
    Abstract: Mesenchymal stern cells which express TNF-? receptor Type I in an amount of at least 13 pg/106 cells. Such mesenchymal stem cells inhibit the proliferation of lymphocytes and may be employed, in particular, in the treatment of graft-versus-host disease.
    Type: Application
    Filed: February 22, 2012
    Publication date: August 23, 2012
    Inventors: Alla Danilkovitch, Diane Carter, Alicia Tyrell, Simon Bubnic, Michelle Marcelino, Rodney Monroy
  • Publication number: 20110189768
    Abstract: Mesenchymal stem cells which express TNF-? receptor Type I in an amount of at least 13 pg/106 cells. Such mesenchymal stem cells inhibit the proliferation of lymphocytes and may be employed, in particular, in the treatment of graft-versus-host disease.
    Type: Application
    Filed: April 13, 2011
    Publication date: August 4, 2011
    Inventors: Alla Danilkovitch, Diane Carter, Alicia Tyrell, Simon Bubnic, Michelle Marcelino, Rodney Monroy
  • Publication number: 20090169522
    Abstract: Mesenchymal stem cells which express TNF-? receptor Type I in an amount of at least 13 pg/106 cells. Such mesenchymal stem cells inhibit the proliferation of lymphocytes and may be employed, in particular, in the treatment of graft-versus-host disease.
    Type: Application
    Filed: January 5, 2007
    Publication date: July 2, 2009
    Inventors: Alla Danilkovitch, Diane Carter, Alicia Tyrell, Simon Bubnic, Michelle Marcelino, Rodney Monroy
  • Publication number: 20070258963
    Abstract: Mesenchymal stem cells which express TNF-{acute over (?)} receptor Type I in an amount of at least 13 pg/106 cells. Such mesenchymal stem cells inhibit the proliferation of lymphocytes and may be employed, in particular, in the treatment of graft-versus-host disease.
    Type: Application
    Filed: January 5, 2007
    Publication date: November 8, 2007
    Inventors: Alla Danilkovitch, Diane Carter, Alicia Tyrell, Simon Bubnic, Michelle Marcelino, Rodney Monroy